Moreover, we carried out an in vitro limiting-dilution assay to ascertain whether SMYD3 pharmacological inhibition could impair the self-renewal activity of patient-derived CRC-SCs and found that treatment with EM127 reduced their sphere-initiating cell frequency (Supplementary Fig. 4c). The gene discussed is SMYD3; the disease is colorectal carcinoma.